Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1632 1653 1682
This examiner grants 27% of resolved cases
Risa Takenaka has resolved 22 cases in Art Unit 1600. The allowance rate is 27.3 percent, and the interview lift is 100.0 percent. The median days to allowance is 1431. These metrics from Tech Center 1600 indicate a challenging baseline for applicants, though the lift suggests interviews are highly impactful. The 1431-day median reflects a lengthy prosecution process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18613041 | REAGENTS AND METHODS FOR PROMOTING ARTERIAL ENDOTHELIUM DIFFERENTIATION AND NITRIC OXIDE PRODUCTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18005167 | METHODS ENABLING INFECTION AND DIFFERENTIATION OF HUMAN DISTAL LUNG ORGANOIDS BY SARS-COV-2 AND OTHER PATHOGENS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17779427 | IN VITRO CELL BASED POTENCY ASSAY | Non-Final OA | Merck Sharp & Dohme LLC |
| 17754050 | COMPOSITIONS AND METHODS FOR MODULATING GENOMIC COMPLEX INTEGRITY INDEX | Non-Final OA | Flagship Pioneering Innovations V, Inc. |
| 18263471 | METHODS FOR INCREASING VIRAL TRANSDUCTION OF CELLS | Final Rejection | Trustees of Dartmouth College |
| 18387165 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18296224 | TREATMENT OF CANAVAN DISEASE | Non-Final OA | CITY OF HOPE |
| 18020823 | PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17904581 | METHOD FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | Non-Final OA | Mesoblast International Sárl |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy